View Older Stories View More Recent Stories
-
Evercore ISI Upgrades Amgen (AMGN) to Outperform
-
Evercore ISI Starts Phathom Pharmaceuticals (PHAT) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Evercore's former famed biotech analyst Mark Schoenebaum has passed away
-
Evercore ISI Downgrades Teva Pharma (TEVA) to In Line
-
UPDATE: Evercore ISI Upgrades Dova Pharmaceuticals Inc (DOVA) to Outperform
-
UPDATE: Allergan (AGN) Sees Mid-Day Gains
-
Macrogenics (MGNX) Could Trade to $2B+ Valuation - Evercore ISI
-
Evercore ISI Downgrades Amgen (AMGN) to In Line
-
Ravi Mehrotra Joins Evercore ISI Research Team
-
Evercore ISI Starts Molecular Templates (MTEM) at Outperform
-
Evercore ISI Recognized as the Top Ranked Independent Firm in U.S. Equity Research
-
Pre-Open Movers 08/24: (ADSK) (SPLK) (BKE) (NFLX) Higher; (HIBB) (GPS) (ROST) Lower (more...)
-
Evercore ISI Upgrades Mylan (MYL) to Outperform
-
Teva Pharma (TEVA) Confident in Branded Business Trends, No Plans to Raise Equity - Evercore ISI
-
Celgene (CELG) PT Lowered to $112 at Evercore ISI, Keeps 'Outperform'
-
Formulary Update Positive for Mylan (MYL) - Evercore ISI
-
News on Novartis' Gilenya Patents Positive for Celgene (CELG) - Evercore ISI
-
Celgene's (CELG) EU Revlimid Settlement Slightly Below Expectations - Evercore ISI
-
Amgen (AMGN) Aimovig TRx Overstated IMS Says - Evercore ISI
-
Gilead Sciences (GILD) on Watch Following GSK Ph 3 GEMINI Trials
-
Evercore ISI Starts MacroGenics (MGNX) at Outperform
-
Evercore ISI Sees Under the Radar Driver for Jazz Pharmaceuticals (JAZZ)
-
Celgene (CELG) Revlimid Discussed by HHS Secretary Azar - Evercore ISI
-
Evecore ISI Doesn't Think Merck (MRK) KN-407 Failed
-
UPDATE: Celgene (CELG) metabolite controversy is overdone - Evercore ISI
-
UPDATE: Dicerna Pharmaceuticals (DRNA) PT Raised to $17 at Evercore ISI Amid Settlement
-
UPDATE: Evercore ISI Downgrades Alkermes (ALKS) to In Line
-
Evercore ISI Starts Pieris Pharmaceuticals (PIRS) at Outperform
-
Medicines Co. (MDCO) Provides Important Update on Ph 3 RNAi Program - Evercore ISI
-
ODYSSEY Results Seen as Positive for Medicines Co. (MDCO)
-
UPDATE: Evercore ISI Starts miRagen Therapeutics (MGEN) at Outperform
-
Jazz Pharmaceuticals (JAZZ) Xyrem Competitor Delayed - Evecore ISI
-
Teva Pharma (TEVA) Leaving Room for Upside Surprise in EBITDA Guidance - Evercore ISI
-
UPDATE: Evercore ISI Starts Dicerna Pharmaceuticals (DRNA) at Outperform; Alnylam Case Appears Favorable
-
Biogen (BIIB) Defended at Evercore ISI; BAN-2401 Data Should Not Move Stock
-
Mylan (MYL) Positioned for Possible Late 2019/2010 Launch of Glargine - Evercore ISI (SNY)
-
Evercore ISI Starts Apellis Pharmaceuticals (APLS) at Outperform
-
Valeant Pharma (VRX) in 'Very Good Shape' on Debt Covenants - Evercore ISI's Raffat
-
GSK (GSK) Not Trying to Break Price in HIV with Dulo, Positive for Gilead Sciences (GILD) - Evercore ISI Raffat
-
Everore ISI's Raffat Provides Takeaways on Juno Therapeutics (JUNO) ROCKET Trial Data (GILD)
-
Allergan (AGN) Should Be Up - Evercore ISI's Raffat
-
Teva Pharma (TEVA) Files Lawsuit Versus Eli Lilly (LLY) Related to CGRP Mab - Evercore ISI
-
Evercore ISI named #3 in U.S. Equity Research by Institutional Investor's All-America Equity Research Survey
-
UPDATE: Biogen (BIIB), Roche on Watch Amid Potential New PML case on Ocrevus
-
Too Much 'Confusion and Nervousness' in Allergan (AGN) - Evercore ISI

